{"id":997404,"date":"2026-08-24T07:06:46","date_gmt":"2026-08-24T11:06:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ashland-advances-high-growth-oral-biologics-delivery-applications-with-launch-of-permexa-sodium-caprate\/"},"modified":"2026-08-24T07:06:46","modified_gmt":"2026-08-24T11:06:46","slug":"ashland-advances-high-growth-oral-biologics-delivery-applications-with-launch-of-permexa-sodium-caprate","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ashland-advances-high-growth-oral-biologics-delivery-applications-with-launch-of-permexa-sodium-caprate\/","title":{"rendered":"Ashland advances high-growth oral biologics delivery applications with launch of permexa\u2122 sodium caprate"},"content":{"rendered":"

\nCommercialization follows strong interest from pharmaceutical developers worldwide
\n<\/h2>\n
\n

WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH), is announcing the launch of permexa\u2122 sodium caprate,<\/b> a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.\u00a0<\/p>\n

The launch comes at a time of significant market momentum in oral peptide and biologics development. Pharmaceutical companies continue to invest heavily in oral alternatives to injectable therapies, driven by the potential to improve patient convenience, enhance treatment adherence and unlock new therapeutic opportunities. As a result, pipelines across GLP-1\u2019s, diabetes and weight loss, metabolic disorders, endocrine\u00a0therapeutics\u00a0and other peptide-based medicines continue to expand.\u00a0<\/p>\n

Developers continue to face important challenges as programs move from concept through development and manufacturing, despite growing investment and encouraging clinical progress. Permeability enhancement\u00a0remains\u00a0critical for oral drug products, but formulation consistency, process\u00a0robustness\u00a0and scalability are increasingly recognized as key barriers to successful commercialization.\u00a0<\/p>\n

Ashland permexa\u2122 sodium caprate was engineered to help address these challenges by combining established sodium caprate functionality with improved pharmaceutical processing performance. The excipient is designed with an IP-protected process to support more robust tablet manufacturing through improved powder flow, enhanced\u00a0compressibility\u00a0and greater formulation consistency, while\u00a0maintaining\u00a0the permeability enhancement characteristics required for oral drug delivery applications.\u00a0The result is a solution intended not only for laboratory success, but also for real-world pharmaceutical development and manufacturing environments where reproducibility, scalability and process robustness are essential.\u00a0<\/p>\n

The Ashland launch follows strong interest from pharmaceutical developers worldwide. Ahead of the commercial launch, the company recorded engagement with multiple\u00a0pharmaceutical, biotech and CDMO organizations globally, spanning sampling activities, technical evaluations, pre-launch sales, benchmarking\u00a0studies\u00a0and formulation development discussions. Customer feedback has been overwhelmingly positive on\u00a0the product\u2019s differentiated properties.\u00a0<\/p>\n

\u201cThe rapid growth of oral peptide development is creating demand for excipients that support both biological performance and pharmaceutical manufacturability,\u201d said Alessandra Faccin, senior vice president and general manager, Life Sciences, Ashland. \u201cPermexa\u2122 sodium caprate was engineered to help customers address complex challenges and move more confidently from formulation through commercialization. The level of engagement we have seen prior to launch\u00a0demonstrates\u00a0the importance of solutions that support both drug delivery performance and scalable manufacturing.\u201d\u00a0<\/p>\n

Caroline Cooreman, strategy director, Life Sciences, Ashland, continued, \u201cConsequently, Ashland is not stopping here. We have developed a multi-stage strategy to support the pharmaceutical market with essential excipients for the oral delivery of biologics. We have multiple\u00a0additional products in the\u00a0pipeline and recognize important synergies with our vinyl pyrrolidone and derivatives (VP&D) portfolio.\u00a0We are already actively servicing this market with our established VP&D portfolio, which will be further strengthened by our oral\u00a0biologics\u2019\u00a0portfolio expansion,\u201d she concluded.<\/p>\n

For more information about\u00a0Permexa\u2122 sodium caprate and how the expanded Ashland portfolio of solutions for oral biologics delivery\u2014including product information, technical\u00a0support\u00a0and sampling opportunities\u2014 interested parties should visit http:\/\/ashland.com\/permexa<\/a> \u00a0or contact their local Ashland solver.\u00a0<\/p>\n

\n FORWARD-LOOKING STATEMENTS<\/b>
\n
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cis likely,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201cobjectives,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cplans\u201d and \u201cintends\u201d and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its Annual Report to Stockholders, quarterly reports and other filings with the Securities and Exchange Commission (\u201cSEC\u201d), news releases and other written and oral communications. These forward-looking statements are based on Ashland\u2019s expectations and assumptions, as of the date such statements are made, regarding Ashland\u2019s future operating performance and financial condition, its strategy as well as the economy and other future events or circumstances.<\/p>\n

The risks and uncertainties we face which may cause our actual results to differ materially from the results expressed, projected, or implied in these forward-looking statements include, but are not limited to: Ashland\u2019s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland\u2019s products; risks inherent in operating a global business, including tariffs and other trade policies, geopolitical instability and armed conflict, and challenges associated with hiring and managing a diverse workforce across countries with differing laws, regulations, and cultural practices; economic downturns and disruptions in the financial markets; Ashland\u2019s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland\u2019s information technology systems and networks, malicious cyberattacks, and the inadvertent or accidental disclosure or loss of proprietary or sensitive information; Ashland\u2019s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; and changes in taxation or adverse tax rulings. These risks and uncertainties also include, but are not limited to, the risk factors set forth in Item 1A. \u201cRisk Factors\u201d of Ashland\u2019s most recent Form 10-K, and in our other periodic reports filed with the SEC. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update publicly any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise. Information on Ashland\u2019s website is not incorporated into or a part of this presentation.<\/p>\n

\n About Ashland<\/b>
\n
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers \u2013 from renowned scientists and research chemists to talented engineers and plant operators \u2013 thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit\u00a0ashland.com<\/a>\u00a0and\u00a0ashland.com\/ESG<\/a>\u00a0to learn more.<\/p>\n

\n \u2122<\/sup> Trademark, Ashland or its subsidiaries, registered in various countries.<\/p>\n

\n FOR FURTHER INFORMATION:<\/b>\n <\/p>\n\n\n\n\n\n
\n Investor Relations:<\/b>\n <\/td>\n\n Media Relations:<\/b>\n <\/td>\n<\/tr>\n
Sandy Klugman<\/td>\nCarolmarie C. Brown<\/td>\n<\/tr>\n
+1 (302) 594-7777<\/td>\n+1 (302) 995-3158<\/td>\n<\/tr>\n
\n sandy.klugman@ashland.com<\/u>\n <\/td>\n\n ccbrown@ashland.com<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

\n Attachments<\/strong>\n <\/p>\n